PDCD1 and glioblastoma: The Ivy Foundation Early Clinical Trials Consortium conducted a multi-institutional, randomized clinical study to evaluate immunological response and survival in 35 patients with recurrent, surgically resectable GBM after neoadjuvant anti-PD-1 immunotherapy with pembrolizumab (228).